Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Mar 27, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Innate Pharma filed a 6-K on 3/27/25, incorporating CEO statements by reference.
AI Summary
Innate Pharma S.A. filed a Form 6-K on March 27, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that the company files annual reports under Form 20-F. The document includes an incorporation by reference section, referencing Exhibit 99.1, which contains statements from CEO Jonathan Dickinson.
Why It Matters
This filing provides routine updates for investors and regulatory bodies, ensuring transparency regarding the company's ongoing reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing that does not appear to contain significant new financial or operational information.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- Jonathan Dickinson (person) — Chief Executive Officer
- March 27, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It is used to furnish information that the company has made or is required to make public pursuant to the laws of its home country.
Which form does Innate Pharma S.A. use for its annual reports?
Innate Pharma S.A. files its annual reports under cover of Form 20-F.
What is the principal executive office address of Innate Pharma S.A.?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is incorporated by reference into this Form 6-K?
Exhibit 99.1 to this Report on Form 6-K is incorporated by reference, excluding specific quoted statements and webcast information.
When was Innate Pharma, SA's name changed?
The company's name was changed from Innate Pharma, SA on January 29, 2014.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 27, 2025 by Jonathan Dickinson regarding Innate Pharma SA (IPHYF).